Retatrutide is an investigational triple receptor agonist with activity at GIP, GLP-1 and glucagon receptors. NovaMeds groups the 10mg and 20mg vial presentations on one product page.
Available presentations: 10mg and 20mg. Format: solution vials.
Molecule / type: Triple GIP / GLP-1 / glucagon receptor agonist
Listed strengths: 10mg and 20mg
Format: solution vials
Regulatory context: investigational, not approved by regulatory agencies
Retatrutide remains in Phase 3 clinical development as a multi-receptor agonist. Research is focused on metabolic physiology and combined GIP, GLP-1 and glucagon receptor signaling. This page does not provide treatment or dosing guidance.
What strengths are listed?
NovaMeds lists 10mg and 20mg solution vial presentations.
Is retatrutide an approved medicine?
No. Retatrutide remains investigational and is not currently approved by regulatory agencies. NovaMeds does not present it as an approved treatment.
Where can I review quality information?
See the Quality and Product Verification pages for the NovaMeds documentation framework.